- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Chronic migraine
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 983KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 283KB)
Erenumab – November 2024
Erenumab; Solution for subcutaneous injection 70 mg in 1 mL single dose pre-filled pen, Solution for subcutaneous injection 140 mg in 1 mL single dose pre-filled pen; Aimovig®
Last updated
30 May 2025
